ClinicalTrials.Veeva

Menu
R

Research Institute of South Florida | Miami, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Bococizumab
Verekitug
Astegolimab
UPB-101
SAR440340
Lebrikizumab
Ensifentrine
LY2951742
JNJ-53718678
VK2809

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 37 total trials

A Phase 2b Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pul...

Enrolling
Chronic Obstructive Pulmonary Disease
Other: Placebo
Drug: Verekitug

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Enrolling
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Astegolimab
Drug: Placebo

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Astegolimab

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab (SAR440340)

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate t...

Active, not recruiting
Severe Asthma
Drug: Placebo
Drug: Verekitug (UPB-101)

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Enrolling
Obesity
Drug: Placebo
Drug: Maridebart Cafraglutide

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to...

Enrolling
Asthma
Drug: Placebo
Drug: Dupilumab

This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma.The purpose of this study is...

Enrolling
Asthma
Drug: Short-Acting Beta Agonists (SABA)
Drug: Fluticasone/salmeterol

Primary Objective:Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety o...

Enrolling
Hyperuricemia
Gout Flare
Drug: Placebo
Drug: Tigulixostat

Trial sponsors

Roche logo
Sanofi logo
BioNTech logo
Pfizer logo
Ferring logo
Janssen (J&J Innovative Medicine) logo
Janssen (J&J Innovative Medicine) logo
U
Amgen logo
Boehringer Ingelheim logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems